- CVS Health Corp CVS is capping purchases of rapid, over-the-counter COVID-19 tests, with a maximum of six packages available online and four in its pharmacies.
- The limits apply to Abbott Laboratories' ABT BinaxNOW along with a test from Ellume, according to an email from a CVS spokesperson, Bloomberg reported.
- Both tests are available without a prescription. The spread of the delta variant has resulted in a surge in demand for rapid virus tests, thus making the products scarce at some online retailers and in certain stores.
- The CVS spokesperson said that the online availability of rapid COVID-19 tests could shift based on demand.
- CVS said it is working with its suppliers to meet rising needs.
- According to the email, the change was made this week "to serve our customers' OTC testing needs, and due to high demand," according to the email.
- Related Content: Abbott Destroyed Several COVID Test Cards, Now Faces Diminished Capacity
- Price Action: CVS stock closed 0.65% lower at $83.03, while ABT stock closed 0.59% higher at $125.47 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in